Evidence-Based Medicine Sliding Into Market Economy-Based Medicine

Evidence-based medicine was conceived as a safeguard — a commitment to letting rigorous data, rather than tradition or authority, guide clinical decisions. Few would argue with that founding principle. Yet something has shifted. Across cardiology, gastroenterology, and beyond, a pattern is emerging that deserves serious scrutiny: the systematic alignment of clinical evidence with commercial imperatives. The 2024 European Congress of Cardiology lowered its blood pressure thresholds to match American standards, instantly expanding the pool of patients eligible for treatment. Specialists commenting online were blunt about their suspicions: that pharmaceutical market expansion, not improved patient outcomes, was the primary driver. Whether or not that suspicion is entirely fair, the question it raises is legitimate. When diagnostic thresholds shift in ways that consistently favor treatment over watchful waiting, we should ask who benefits. The pattern repeats across drug classes. Each generation of newer, more expensive medications arrives accompanied by studies that subtly diminish confidence in existing ones — not by proving inferiority directly, but by reframing the clinical question. Statins once displaced earlier lipid-lowering agents; now the groundwork is being laid for lipoprotein inhibitors to displace statins. The clinical case for each transition is presented in the language of evidence, but the economic logic underneath is rarely examined with equal rigor. Meanwhile, genuine questions persist: Is clopidogrel meaningfully superior to aspirin for most patients, or merely more profitable? Are newer oral anticoagulants truly an advance over warfarin in all contexts, or are we discarding a cheap, well-understood drug prematurely? The design of clinical trials deserves particular scrutiny. When a new drug is tested not against the existing standard of care alone, but in combination with it, a negative outcome becomes structurally difficult to produce. The new agent can claim additive benefit without ever being required to prove superiority. This is not science in the service of patients. It is science in the service of investment returns. The stent scandals in the United States illustrate where this logic ultimately leads. Devices were implanted in patients who did not need them, justified by selective readings of evidence-based guidelines, driven by financial incentives for hospitals and physicians. Patients bore the procedural risks and the long-term burden of antiplatelet therapy, while the institutional beneficiaries collected the revenue. Those responsible did not operate outside evidence-based medicine — they operated within its language while hollowing out its purpose. Anti-Helicobacter therapy offers another case worth examining. Rather than pursuing a deeper understanding of the underlying mechanisms of ulcer disease, clinical practice has drifted toward escalating polypharmacy — combinations of increasing complexity that strain patients and resist resolution. This is not optimization. It is the perpetuation of a treatment model that serves pharmaceutical volume more than patient welfare. Evidence-based medicine remains an essential framework. But evidence can be shaped, selectively reported, and strategically deployed. When the principle of optimality — the question of whether a given intervention genuinely produces the best outcome at the least cost to the patient — is absent from the design and interpretation of research, evidence-based medicine loses its moral foundation. Restoring that foundation requires not cynicism about science, but vigilance about whose interests science is being made to serve. You can learn more by reading our e-book or listening to our audiobook